The Year in cardiology 2015

doi:10.3969/j.issn.1004-583X.2016.02.002

Abstract

Abstract: A lot of advances in cardiology occurred in the year 2015, especially in the respects of hypertension, heart failure, coronary artery disease, lipid lowering, cardiac arrhythmias, and deep vein thrombosis/pulmonary embolism. This review focuses on the blood pressure control, treatment of chronic heart failure and coronary artery disease, new drugs in lipid lowering, treatment strategies for cardiac arrhythmias and pulmonary embolism.

Key words: hypertension, heart failure, coronary artery disease, lipid, cardiac arrhythmia, deep vein thrombosis/pulmonary embolism, diagnosis, treatment, guideline

CLC Number:

R541

Cui Wei. The Year in cardiology 2015[J]. Clinical Focus, 2016, 31(2): 123-130.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.02.002

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I2/123

References

[1] Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control[J]. N Engl J Med, 2015, 373(22): 2103-2116.
[2] Sundstrm J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and Meta-analysis[J]. Ann Intern Med, 2015,162(3):184-191.
[3] Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study[J]. BMJ, 2015,350:h158.
[4] Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal[J]. Circ Res, 2015, 116(6): 1058-1073.
[5] 耿雪, 崔炜. 强化降压是否有益的Meta分析[J]. 临床荟萃, 2015, 30(11): 1226-1235.
[6] Magee LA, von DP, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy[J]. N Engl J Med, 2015,372(5):407-417.
[7] Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial[J]. JAMA, 2015,313(13):1325-1335.
[8] Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension[J]. J Am Coll Cardiol, 2015,65(18):1998-2038.
[9] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2015,43(5):380-393.
[10] Daskalopoulou SS, Rabi DM, Zarnke KB, et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension[J]. Can J Cardiol, 2015,31(5):549-568.
[11] Stranges PM, Drew AM, Rafferty P, et al. Treatment of hypertension with chronotherapy: is it time of drug administration?[J]. Ann Pharmacother, 2015, 49(3):323-334.
[12] Kasiakogias A, Tsioufis C, Thomopoulos C, et al. Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study[J]. J Hypertens, 2015,33(2):393-400.
[13] Bonten TN, Snoep JD, Assendelft WJ, et al. Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial[J]. Hypertension, 2015,65(4):743-750.
[14] Hu X, Fan J, Chen S, et al. The role of continuous positive airway pressure in blood pressure control for patients with obstructive sleep apnea and hypertension: a meta-analysis of randomized controlled trials[J]. J Clin Hypertens (Greenwich), 2015,17(3):215-222.
[15] Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial[J]. Lancet, 2015, 386(1008): 2059-2068.
[16] Liu G, Zheng XX, Xu YL, et al. Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis[J]. J Hum Hypertens, 2015,29(3):159-166.
[17] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014,371(11):993-1004.
[18] McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure[J]. Eur Heart J, 2015, 36(7): 434-439.
[19] 张健,张宇辉.代表中国心力衰竭注册登记协作组. 多中心、前瞻性中国心力衰竭注册登记研究:病因、临床特点和治疗情况初步分析[J]. 中国循环杂志, 2015,30(5):413-416.
[20] Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine - short version[J]. Eur Heart J, 2015,36(30):1958-1966.
[21] Alehagen U, Benson L, Edner M, et al. Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish heart failure registry[J]. Circ Heart Fail, 2015,8(2):252-260.
[22] Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials[J]. Eur Heart J, 2015,36(24):1536-1546.
[23] Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF[J]. Eur J Heart Fail, 2015,17(4):434-441.
[24] Kiernan MS, Gregory D, Sarnak MJ, et al. Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure[J]. JACC Heart Fail, 2015,3(3):214-223.
[25] Wang ZQ, Zhang R, Chen MT, et al. Digoxin is associated with increased all-cause mortality in patients with atrial fibrillation regardless of concomitant heart failure: a Meta-analysis[J]. J Cardiovasc Pharmacol, 2015,66(3):270-275.
[26] Khazanie P, Heizer GM, Hasselblad V, et al. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models[J]. Am Heart J, 2015, 170(2):290-297.e1.
[27] Ribeiro A, Lourenco P, Silva S, et al. Predictors of natriuretic peptide non-response in patients hospitalized with acute heart failure[J]. Am J Cardiol, 2015,115(1):69-74.
[28] Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting[J]. BMJ, 2015,350:h910.
[29] Watson CJ, Gupta SK, O'Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure[J]. Eur J Heart Fail, 2015,17(4):405-415.
[30] Wong LL, Armugam A, Sepramaniam S, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction[J]. Eur J Heart Fail, 2015,17(4):393-404.
[31] Melman YF, Shah R, Danielson K, et al. Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study[J]. Circulation, 2015,131(25):2202-2216.
[32] Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis[J]. Eur Heart J, 2015,36(46):3238-3249.
[33] Washam JB, Herzog CA, Beitelshees AL, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientificstatement from the American Heart Association[J]. Circulation, 2015, 131(12):1123-1149.
[34] Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association[J]. Circulation, 2015,131(10):927-964.
[35] Pandit A, Giri S, Hakim FA, et al. Shorter (</=6 months) versus longer (>/=12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials[J]. Catheter Cardiovasc Interv, 2015, 85(1):34-40.
[36] Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials[J]. BMJ, 2015,350:h1618.
[37] Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and Meta-analysis of randomized controlled trials[J]. J Am Coll Cardiol, 2015,65(13):1298-1310.
[38] 崔炜. 解读最新证据:再议双联抗血小板治疗持续时间问题[J]. 中国介入心脏病学杂志, 2015,23(3):173-176.
[39] Hwang IC, Jeon JY, Kim Y, et al. Statin therapy is associated with lower all-cause mortality in patients with non-obstructive coronary artery disease[J]. Atherosclerosis, 2015,239(2):335-342.
[40] Giacoppo D, Gargiulo G, Aruta P, et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients[J]. BMJ, 2015,351:h5392.
[41] Sethi A, Malhotra G, Singh S, et al. Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network Meta-analysis of randomized controlled trials[J]. Circ Cardiovasc Interv, 2015,8(11):e002778.
[42] Stub D, Smith K, Bernard S, et al. Air versus oxygen in ST-segment-elevation myocardial infarction[J]. Circulation, 2015,131(24):2143-2150.
[43] Goldberger JJ, Bonow RO, Cuffe M, et al. Effect of beta-blocker dose on survival after acute myocardial infarction[J]. J Am Coll Cardiol, 2015,66(13):1431-1441.
[44] Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future[J]. Eur Heart J, 2015,36(36):2415-2424.
[45] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med, 2015,372(25):2387-2397.
[46] Bangalore S, Breazna A, DeMicco DA, et al. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT Trial[J]. J Am Coll Cardiol, 2015,65(15):1539-1548.
[47] Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy[J]. Atherosclerosis, 2015, 238(2): 329-335.
[48] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) [J]. Eur Heart J, 2015, 36(41): 2793-2867.
[49] Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope[J]. Heart Rhythm, 2015,12(6):e41-e63.
[50] Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement[J]. Circulation, 2015,132(5):441-453.
[51] Freeman JV, Reynolds K, Fang M, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN Study[J]. Circ Arrhythm Electrophysiol, 2015,8(1):49-58.
[52] Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) [J]. Lancet, 2015,385(9985):2363-2370.
[53] Ouyang AJ, Lv YN, Zhong HL, et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation[J]. Am J Cardiol, 2015,115(7):901-906.
[54] Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature[J]. Eur Heart J, 2015, 36(28):1831-1838.
[55] Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort[J]. J Am Coll Cardiol, 2015,65(25):2691-2698.
[56] Bansch D, Bonnemeier H, Brandt J, et al. Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial[J]. Eur Heart J, 2015,36(37):2500-2507.
[57] Healey JS, Hohnloser SH, Glikson M, et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE) [J]. Lancet, 2015,385(9970):785-791.
[58] Miller MA, Neuzil P, Dukkipati SR, et al. Leadless cardiac pacemakers: back to the future[J]. J Am Coll Cardiol, 2015,66(10):1179-1189.
[59] Reddy VY, Exner DV, Cantillon DJ, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker[J]. N Engl J Med, 2015, 373(12): 1125-1135.
[60] Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial[J]. Lancet, 2015, 386(10005): 1747-1753.
[61] Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation and future risk of venous thromboembolism:the Tromso study[J]. J Thromb Haemost, 2015, 13(1):10-16.
[62] Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial[J]. JAMA, 2015,313(16):1627-1635.
[63] Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial[J]. JAMA, 2015,314(1):31-40.